Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought

This article was originally published in The Gray Sheet

Executive Summary

BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year

You may also be interested in...



FDA Review Criteria Are Insufficient To Prompt CMS Coverage – Feigal, Tunis

Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11

FDA/CMS Device Trade Secret Memo Added To Regulatory Reform Wish List

FDA and CMS should issue a memorandum of understanding on maintaining confidentiality and trade secrets during collaborations between the agencies in evaluating new devices, according to the HHS Secretary's Advisory Committee on Regulatory Reform

BioLuminate's Smart Probe Breast Cancer Detection Trials Start In Early 2001

San Jose-based BioLuminate expects to be profitable in 2003, immediately following the commercial release of its Smart Probe breast cancer detection diagnostic tool. The privately held start-up began operations in April 2000.

Latest News
See All
UsernamePublicRestriction

Register

MT017754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel